NCT01589237View on ClinicalTrials.gov

Extension to a Randomized, Double-blind, Placebo Controlled Study of LCQ908 in Subjects With Familial Chylomicronemia Syndrome.

PHASE3TerminatedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

February 28, 2013

Primary Completion Date

July 31, 2015

Study Completion Date

July 31, 2015

Conditions
Familial Chylomicronemia Syndrome (FCS) (HLP Type I)
Interventions
DRUG

LCQ908

Trial Locations (10)

7925

Novartis Investigative Site, Cape Town

20246

Novartis Investigative Site, Hamburg

44093

Novartis Investigative Site, Nantes

75651

Novartis Investigative Site, Paris

98104

Novartis Investigative Site, Seatlle

G7H 7P2

Novartis Investigative Site, Chicoutimi

G1V4M6

Novartis Investigative Site, Ste-Foy

H2W1R7

Novartis Investigative Site, Ouest-Montreal

1105 AZ

Novartis Investigative Site, Meibergdreef 9

M13 9NT

Novartis Investigative Site, Manchester

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY